Figures at a glance

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

FIGURE 1

Figure 1: Treatment timeline: Treatment course of advanced tongue base SCC from diagnosis until expiration

FIGURE 2

Figure 2: PET scan (Jan.12, 2018): recurrent local oropharyngeal tumor (rT2N0M0, stage II) over tongue base, vallecula, and epiglottis

FIGURE 3

Figure 3: Clinically relevant mutations of TP53, detected in patient’s re-biopsy specimen

FIGURE 4

Figure 4: Copy number profile of the re-biopsy sample. Amplified regions of chromosome 7 are indicated by red “dots,” which cover the EGFR coding regions

FIGURE 5

Figure 5: (a) PET scan (Jun.19, 2018); (b) MRI (Jun.4, 2018): corresponding images illustrating smaller local tumor through the first phase genomic analysis-guided target therapy, with MRI (b) as the baseline follow-up image with enhanced tongue base, vallecula, and epiglottis

FIGURE 6

Figure 6: (a) MRI (Dec.17, 2018): progressive local enhanced tumor after the first phase target therapy; (b) MRI (Mar.21, 2019): less enhanced (remitted) local tumor through the second phase target therapy; (c) MRI (the last follow-up image, Oct.18, 2019): invisible enhanced local tumor (previously over tongue base, vallecula and epiglottis), during the second phase target therapy, after partial epiglottectomy of necrotic part of epiglottis